Dermatology Reports · Published 2026-07-22 · DOI 10.4081/dr.2026.10839
Gaetano Licata, Anna Balato, Giuseppe Argenziano, Caterina Mariarosaria Giorgio
Dear Editor, Kimura disease (KD) is a rare, chronic inflammatory condition characterized by subcutaneous nodules, lymphadenopathy, peripheral and tissue eosinophilia, and markedly elevated serum IgE concentrations. Although its precise etiopathogenesis remains incompletely defined, accumulating evidence supports its classification as a type 2 immune-mediated disorder, sustained by Th2 lymphocyte activation and overexpression of interleukin (IL)-4 and IL-13 signaling pathways. This immunological milieu promotes eosinophilic infiltration, vascular proliferation, IgE overproduction, and persistent pruritus, ultimately driving both systemic and cutaneous manifestations of the disease. [...]
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Licata, G., Balato, A., Argenziano, G., et al. (2026). Dupilumab as a targeted therapeutic strategy for Th2-driven cutaneous manifestations in Kimura disease. Dermatology Reports. https://doi.org/10.4081/dr.2026.10839